California’s New Reverse Payment Law Departs from Supreme Court Standard in FTC v. Actavis

Click here to read the full article online

On October 7, 2019, California became the first state to enact legislation—Assembly Bill 824 (“AB 824”)—rendering certain pharmaceutical patent litigation settlement agreements presumptively anticompetitive.1 This alert provides a brief summary of some of the key provisions as written; the final implications of this statute await judicial review.